Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Scleroderma, or systemic sclerosis (SSc), is a diffuse connective tissue disease
characterized by changes in the skin, blood vessels, skeletal muscles, and internal organs.
The purpose of this study is to determine the safety and value of self bone marrow
transplants after chemotherapy in patients with severe SSc.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborators:
Amgen Genzyme, a Sanofi Company University of Pittsburgh